AstraZeneca PLC
AZN
$73.95
$0.861.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00% | 15.48% | 18.03% | 13.81% | 10.45% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00% | 15.48% | 18.03% | 13.81% | 10.45% |
| Cost of Revenue | 17.27% | 15.99% | 20.32% | 75.77% | 43.53% |
| Gross Profit | 14.52% | 15.37% | 17.55% | 5.91% | 5.32% |
| SG&A Expenses | 5.72% | 5.81% | 8.69% | -0.21% | 3.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 5.99% | 75.88% | 81.25% | 78.34% | 74.84% |
| Total Operating Expenses | 11.96% | 13.60% | 16.88% | 19.60% | 16.68% |
| Operating Income | 25.32% | 21.85% | 22.03% | -1.02% | -6.54% |
| Income Before Tax | 29.40% | 24.96% | 25.97% | 16.84% | 28.03% |
| Income Tax Expenses | 32.28% | 37.36% | 75.91% | 62.33% | 1,202.54% |
| Earnings from Continuing Operations | 28.81% | 22.80% | 18.12% | 10.09% | 4.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -40.00% | -66.67% | 0.00% | 37.50% | 16.67% |
| Net Income | 28.80% | 22.76% | 18.14% | 10.16% | 4.51% |
| EBIT | 25.32% | 21.85% | 22.03% | -1.02% | -6.54% |
| EBITDA | 18.83% | 15.95% | 15.84% | -0.26% | -5.27% |
| EPS Basic | 28.72% | 22.72% | 18.12% | 10.16% | 4.51% |
| Normalized Basic EPS | 28.61% | 25.36% | 25.02% | -1.07% | -7.30% |
| EPS Diluted | 28.81% | 22.35% | 17.74% | 9.61% | 4.14% |
| Normalized Diluted EPS | 28.64% | 25.33% | 24.99% | -1.15% | -7.36% |
| Average Basic Shares Outstanding | 0.06% | 0.03% | 0.02% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.05% | 0.06% | 0.05% | 0.06% | 0.05% |
| Dividend Per Share | 5.39% | 6.90% | 6.90% | 2.41% | 2.41% |
| Payout Ratio | -0.14% | -0.10% | -0.13% | -0.06% | -0.04% |